LUND, Sweden, Dec. 17, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect...
Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome )
Also on site :
- Astros To Promote Jacob Melton
- Jamie Dimon warns that the US’s biggest problem is not China but ‘the enemy within’
- At least 21 Palestinians killed while heading to Gaza aid hub, hospital says